Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02389517 · OUTCOME

Overall Response (Number of Participants With VGPR, CR, sCR)

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant · Source last updated 2026-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
At 12 months

What was measured

Overall response was defined according to IMWG criteria as 1. very good partial response (VGPR) 2. complete response (CR) 3. stringent complete response (sCR)

Groups in this outcome

Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)

Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO

Arm II (Lenalidomide)

Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)14
Arm II (Lenalidomide)17

Reported measurements

VGPR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)3Not reportedNot reportedNot reportedNot reported
Arm II (Lenalidomide)6Not reportedNot reportedNot reportedNot reported
CR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)5Not reportedNot reportedNot reportedNot reported
Arm II (Lenalidomide)5Not reportedNot reportedNot reportedNot reported
sCR
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)2Not reportedNot reportedNot reportedNot reported
Arm II (Lenalidomide)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        6
    title
    VGPR
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      2. group Id
        OG001
        value
        5
    title
    CR
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        0
    title
    sCR
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      17
    units
    Participants
description
Overall response was defined according to IMWG criteria as 1. very good partial response (VGPR) 2. complete response (CR) 3. stringent complete response (sCR)
groups
  1. description
    Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO
    id
    OG000
    title
    Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
  2. description
    Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO
    id
    OG001
    title
    Arm II (Lenalidomide)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
At 12 months
title
Overall Response (Number of Participants With VGPR, CR, sCR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice